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Coronary artery disease (CAD) remains the leading cause of death in the Western soci-
eties. Diabetes mellitus (DM) is one of the highly prevalent diseases, which remarkably
accelerates the development of CAD. Experimental evidence indicates that decreased
bioavailability of coronary endothelial nitric oxide (NO) contributes to the development of
CAD in DM.There are recent studies showing that a selective impairment of NO synthesis
occurs in coronary arteries of DM patients, which is mainly due to the limited availability of
endothelial NO synthase (eNOS) precursor, l-arginine. Importantly, these studies demon-
strated that DM, independent of the presence of CAD, leads to selective up-regulation of
arginase-1. Arginase-1 seems to play an important role in limiting l-arginine availability in the
close proximity of eNOS in vessels of DM patients.This brief review examines recent clin-
ical studies demonstrating the pathological role of vascular arginase-1 in human diabetes.
Whether arginase-1, which is crucial in the synthesis of various fundamental polyamines in
the body, will represent a potent therapeutic target for prevention of DM-associated CAD
is still debated.
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DIABETES LEADS TO A REDUCED AVAILABILITY OF NO IN
CORONARY ARTERIES
Diabetes mellitus is associated with an increased incidence of
cardiovascular diseases accounting for significant morbidity and
mortality in the diabetic population. Coronary artery disease
(CAD) is one of the key manifestations of diabetes-associated
vascular disease, a pathology, which predisposes diabetic patients
to myocardial ischemia. The underlying mechanism(s) of CAD
remain incompletely understood in human diabetes, so that effec-
tive preventive therapeutic strategies cannot be adopted in diabetic
patients.
The coronary flow-reserve, as defined by the ratio of coronary
flow under maximal agonist-induced vasodilation to coronary
flow under resting conditions, is reduced in diabetic patients,
even in the absence of significant stenosis of epicardial coro-
nary arteries (1). Nemes et al. have demonstrated that patients
with type 2 diabetes exhibit a reduced coronary flow-reserve (2),
a condition, which was found to be associated with increased
incidence of future ischemic episode in the heart of diabetic
patients (3). Patients with diabetes exhibit endothelial dys-
function, which is characterized by impaired flow- and acetyl-
choline (ACh)-induced relaxation of brachial artery (4) and
forearm resistance vessels (5). Nitenberg et al. have demon-
strated that coronary artery dilation is impaired in diabetic
patients with angiographically normal coronaries (6). Kaneda et
al. performed a study, in which 165 patients underwent intra-
coronary injection of ACh and found that diabetes was the
strongest predictor for ACh-induced coronary vasospasm (7).
This and other studies concluded that diabetes is associated
with impaired dilator function of coronary arteries and this
is manifested as a reduced vasodilator or even vasoconstrictor
responses (8–10).
Previous studies have shown that animals with experimental
insulin resistance and diabetes exhibit a reduced NO-mediated,
agonist-induced dilation of cerebral, mesenteric, coronary, and
skeletal muscle microvessels (11–16). Studies from our laboratory
demonstrated that in rodent models of type 2 diabetes coronary
arteries exhibit impaired ACh-induced dilation, which is primar-
ily due to the reduced synthesis and/or bioavailability of nitric
oxide (NO) (17–20). Katakam et al. have shown that prior to
the impaired ACh-mediated vasodilation NO-mediated coronary
dilation to insulin is reduced in obese Zucker rats (14). This seems
particularly important as insulin and insulin-like growth factor I
have shown to promote NO-mediated vasodilation (21).
Oxidative stress occurring in response to hyperglycemia and
insulin resistance (14, 22–28) is considered to be one of the
key factors leading to the reduced NO-dependent vasodilation.
To support this scenario, oral administration of the antioxi-
dant vitamin-C prevented the decreases in methacholine-induced
brachial artery dilations in patients with diabetes (29). However,
other studies failed to detect any beneficial effect of antioxidant
therapy in the prevention of diabetes-induced vascular compli-
cations (30, 31). For instance, vitamin-E supplementation for
8 weeks did not restore the reduced ACh- and bradykinin-induced
dilations of brachial arteries in diabetic patients (32). These
aforementioned observations raised questions about the efficacy
of antioxidant therapy in preventing diabetes-related endothe-
lial dysfunction. To solve the apparent controversy recent studies
propose a crucial role for reactive nitrogen species in the devel-
opment of diabetes-related vascular complications (33). The rate
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constant for the reaction between superoxide anion and NO is
three to fivefold greater than the rate of superoxide anion scav-
enged by superoxide dismutase (34). Given that NO via interacting
with superoxide anion generates various reactive nitrogen species,
such as the highly reactive peroxynitrite (ONOO−). ONOO− has
numerous detrimental effects in the cardiovascular system and
plays a crucial role in the development of diabetes-induced vas-
cular pathology (33). ONOO− is a powerful oxidizing agent that
causes rapid depletion of sulfhydryl groups, causes DNA dam-
age, protein oxidation, and nitration of aromatic amino acid
residues in proteins, specifically leading to 3-nitrotyrosin for-
mation (33). Although the endogenous cellular mechanisms to
prevent the deleterious effect of ONOO− are not clearly defined
recent preclinical studies suggest that a more selective targeting of
ONOO− holds considerable potential than the use of conventional
antioxidants (35).
DEFICIENCY OF eNOS COFACTORS IN CORONARY ARTERY
DISEASE
It is known that an adequate level of substrates and cofac-
tors for NO synthases, such as l-arginine (36) and tetrahydro-
biopterin (BH4) is essential for NO synthesis (37, 38). Diabetes
has been shown to interfere with the availability of these cofac-
tors thereby leading to a diminished NO synthesis. To provide
experimental evidence for this scenario Ihlemann et al. demon-
strated that in healthy humans, oral glucose challenge-induced
reduction in forearm blood flow is restored by pre-treatment
with BH4 (39). Co-infusion of BH4 and the endothelial NO
synthase (eNOS) precursor, l-arginine into the forearm of dia-
betic patients prevented ischemia reperfusion-induced endothe-
lial dysfunction in the brachial artery (40). In isolated coro-
nary arterioles of patients with atherosclerosis Tiefenbacher et
al. has shown earlier that in vitro administration of the sta-
ble BH4 analog, sepiapterin enhanced dilation in response to
agonist (41). In a recent study oral BH4 treatment in patients
undergoing heart surgery although augmented total biopterin
levels had no significant effects on dilator function of con-
duit vessels owing to systemic and vascular oxidation of BH4
(42). This latter study warranted the need of further investiga-
tions aiming at effectively restoring eNOS cofactor, BH4 levels.
Underlying mechanism(s) responsible for the reduced vascu-
lar availability of BH4 is not entirely understood in diabetes.
It has been shown that ONOO− directly interacts and reduces
the level of BH4, as it has greater affinity for BH4 than that
of ascorbic acid and glutathione (43). Chen et al. demon-
strated that exposure of human eNOS to ONOO− resulted
in a dose-dependent loss of activity with a marked destabi-
lization of the eNOS dimer (44). In addition, Ishii et al. has
shown that insulin is a potential stimulator of BH4, primar-
ily via activating phosphatidylinositol 3-kinase (45). Due to the
apparent lack of insulin action expression and activity of GTP
cyclohydrolase-I is reduced in insulin resistance states, which ulti-
mately leads to eNOS uncoupling and diminished NO-mediated
dilation of cerebral arteries (46). Whether restoring insulin sen-
sitivity will be associated with “re-coupling” of eNOS has yet to
be elucidated.
L-ARGININE TO PREVENT ENDOTHELIAL DYSFUNCTION IN
PATIENTS WITH CAD
l-arginine, the substrate for NO synthase, is the precursor for
NO synthesis in the vascular endothelium. Earlier clinical stud-
ies indicated that administration of l-arginine may enhance NO
bioavailability and dilate coronary arteries (47). For example,
intra-coronary infusion of l-arginine in patients with CAD
attenuated the vasoconstrictor response to intra-coronary ACh
and increased coronary blood flow (48). Lerman et al. studied
the effect of long-term administration of l-arginine (9 g/day)
on patients with non-obstructive coronary disease and found a
markedly improved coronary vasodilator response to ACh (49).
In contrast, in 30 patients with CAD l-arginine therapy while
significantly increased l-arginine plasma levels had no effect on
NO bioavailability and flow-mediated dilation of brachial artery
(50). Moreover, there is another clinical study, which questioned
the effectiveness of l-arginine therapy in patients with CAD (50).
More importantly, in the Vascular Interaction With Age in Myocar-
dial Infarction (VINTAGE MI) study by Schulman et al. l-arginine
supplementation significantly increased mortality in patients with
myocardial infraction leading to early termination of the trial with
the recommendation that l-arginine supplementation not to be
used in patients with myocardial infarction (51). The underlying
mechanism responsible for the controversial and harmful effects
of l-arginine in this particular patient population remains elusive.
Limited number of studies is available to evaluate the acute and
long-term effects of l-arginine treatment in patients with diabetes.
In a recent large cohort, involving 2236 patients recruited within
the LUdwigshafen RIsk and Cardiovascular Health (LURIC)
study, patients with type 2 diabetes had a significantly lower
l-arginine availability than patients without diabetes (52). A
study has shown that l-arginine treatment (8.3 g/day for 21 days)
improved endothelial dilator function and increased insulin
sensitivity in patients with type 2 diabetes (53). The authors
concluded that l-arginine exerted its beneficial effects through
reducing fasting and postprandial glucose levels and normal-
izing adiponectin/leptin ratio (53). Thus, some evidence indi-
cates that in diabetic patients the level of l-arginine is reduced
and administering l-arginine may improve endothelial function.
Whether this effect is mediated directly via enhancing the vas-
cular availability of NO or indirectly via increasing insulin sen-
sitivity has yet to be elucidated. Taken together, it is possible
that diabetic patients may benefit from l-arginine supplementa-
tion, but several important questions still remain open includ-
ing the safety and efficacy of l-arginine treatment in diabetic
patients with concomitant CAD, especially in those with prior
myocardial infarction.
DOES VASCULAR ARGINASE-1 SELECTIVELY UP-REGULATED
IN HUMAN DIABETES?
It is known that the Km of NO synthase for l-arginine is about
2.9µM. The intracellular concentration of l-arginine ranges from
0.1 to 1.0 mM. Given that it seemed intriguing how administra-
tion of l-arginine would increase the bioavailability of NO –
the arginine-paradox. To solve this apparent controversy previ-
ous studies have shown that up-regulation of arginase, the focal
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enzyme of the urea cycle, via hydrolyzing l-arginine reduces NO
synthesis and, importantly, may contribute to the development
of various vascular diseases (36). Detailed pathological role(s) for
arginase-1 and -2 in various disease models as well as the subcel-
lular mechanisms behind is extensively discussed in other review
articles in this thematic issue. In this review we examine those few
existing clinical studies that focused on altered arginase expression
and its vascular consequences in man.
Vascular endothelial cells metabolize l-arginine mainly by
arginase, which exists as two distinct isoforms, arginase-1 and -2.
Arginase-1 is predominantly expressed in the liver and to a much
lesser extent in other cell types, such as vascular endothelial cells,
whereas expression of arginase-2 is more widespread (54). Circu-
lating arginase-1 level was found significantly higher in patients
with heart failure, when compared to controls; and the level of
circulating arginase-1 further increased with the severity of heart
failure (significant increase between NYHA I/II and NYHA III/IV
groups) (55). When sublingual microcirculation was assessed by
dark field intravital microscopy in heart failure patients the authors
found that topical administration of the arginase inhibitor, nor-
NOHA increased capillary density, a measure of tissue perfusion,
in an NO-dependent manner (55). In patients with essential
hypertension Holowatz and Kenney have found an attenuated NO-
dependent reflex cutaneous vasodilatation, which is enhanced by
arginase inhibitors, BEC, and nor-NOHA, but not with l-arginine
supplementation (56). These studies provided functional evidence
for the role of circulating and also tissue-expressed arginase-1,
which interferes with NO-mediated tissue perfusion.
Both arginase-1 and -2 are expressed in the human heart (54).
In a study by Chen et al. right atrial appendage was obtained
from 13 patients undergoing heart surgery for coronary artery
bypass graft (CABG) with three-vessel CAD and from 13 patients
with valve replacement (non-CAD group). In the whole atrial
homogenates there was a significantly reduced protein expression
of both eNOS and arginase-1 in patients with CAD. Of note that
in this study the CAD group had higher proportion of diabetic
patients (11 out of 13), as compared to the control group (3 out of
13). Given that, the individual impact of CAD and diabetes affect-
ing expression of arginase-1 cannot be examined in this study
(57). In our recent study (10) small coronary arteries were dis-
sected from the atrial appendage of 21 patients without and 20
patients with diabetes. Protein expression of arginase-1 in small
coronary arteries was significantly higher in patients with diabetes.
Arginase-1 expression was abundant in endothelial cells and was
co-localized with eNOS in coronary vessels of diabetic patients, but
not in non-diabetics. We demonstrated that inhibition of arginase,
with l-NOHA caused restoration of endothelium-dependent,
ACh-induced dilation in coronary arterioles of diabetic patients.
Although we proposed an effect of diabetes causing arginase-1 up-
regulation, it is of note that in the study diabetic patients exhibited
a significantly greater proportion of CAD (16 out of 20 versus 9
out of 20 patients), therefore the conclusion regarding the selec-
tive up-regulation of arginase-1 in coronary arteries of diabetic
patients is severely limited. In a very recent study by Shemyakin
et al. the independent impact of diabetes in affecting arginase-1
expression and its functional consequence was evaluated (58).
In 16 patients with CAD and 16 patients with CAD and type 2
diabetes endothelium-dependent and endothelium-independent
increases in forearm blood flow were assessed during intra-arterial
infusion of the arginase inhibitor, nor-NOHA. While forearm
blood flow was significantly lower in both CAD and CAD plus
diabetes groups, when compared to age-matched control group,
nor-NOHA markedly increased blood flow with NO-dependent
manner, with a significantly greater extent in patients with con-
comitant diabetes (58). This key observation provided functional
evidence for the selectively up-regulated arginase-1 in diabetic
patients, in vivo.
Taken together, limited number of clinical studies suggest a
selective up-regulation of arginase-1, which may impair dilator
function of conduit and resistance vessels in diabetic patients,
independent of the presence of concomitant CAD. Further stud-
ies involving higher number of research subjects are needed to
assess the independent impact of increased arginase-1 expres-
sion on coronary artery responsiveness in diabetes. Moreover,
it should be noted that arginase inhibitors, nor-NOHA, and l-
NOHA used in these studies do not have selectivity toward arginase
isoforms (arginase-1 versus arginase-2). Thus, the functional role
for arginase-2 in the development of vasomotor dysfunction can-
not be entirely excluded. In this regard, a previous study has found
that increased expression of arginase-2 leads to decreased NO syn-
thesis in pulmonary endothelial cells of patients with pulmonary
arterial hypertension (59). The pathological role of arginase iso-
forms in diabetes-related coronary microvascular dysfunction also
has yet to be elucidated.
POSSIBLE MECHANISMS LEADING TO SELECTIVE
UP-REGULATION OF ARGINASE-1 IN DIABETIC PATIENTS
The underlying mechanism(s) leading to selective up-regulation
of arginase-1 in coronary arterioles in diabetic patients remains
elusive. One obvious possibility is the known action of insulin,
FIGURE 1 | Mechanisms of coronary artery dysfunction in diabetes.
Schematic draw demonstrates proposed mechanisms by which diabetes
and hyperglycemia lead to up-regulation of arginase-1 resulting in reduced
NO-mediated dilation in human coronary arteries. Alterations in insulin
signaling may contribute to arginase up-regulation, which reduces the level
of l-arginine and thereby limit NO synthesis. ACh: acetylcholine, M3-R: M3
muscarinic receptor, InsR: insulin receptor, sGC: soluble guanylate cyclase,
cGMP: cyclic guanosine monophosphate.
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which suppresses expression and activity of enzymes of urea
synthesis pathway. Since insulin signaling is impaired in type 2
diabetes (patients likely to exhibit insulin resistance) it is possible
that the failure of insulin regulatory action contributes to up-
regulation of arginase-1. In the clinical setting diabetic patients
are on insulin sensitizing and oral anti-diabetic medication or
commonly take insulin. For instance, in the study by Shemyakin et
al. 31 and 56% of patients with CAD plus diabetes were on insulin
and biguanides/sulfonylureas, respectively (58). In our aforemen-
tioned study all patients with diabetes had either anti-diabetic
medication or were on insulin (10). Therefore, the effect of insulin
resistance and the concomitant action of exogenous insulin is
difficult to examine in these investigations. Also, due to the lim-
ited number of diabetic patients involved in the aforementioned
studies further studies are warranted to ascertain the role of
insulin and other pathological factors that could contribute to
increased arginase-1 expression in diabetes. In this context, in a
previous elegant study Kashyap et al. found that plasma arginase
activity is increased in type 2 diabetic patients with reduced activ-
ity of eNOS in the skeletal muscle. Interestingly, these changes
were detected without alterations in the plasma protein levels of
arginase-1 and -2. Importantly, the increased arginase activation
was correlated with the degree of hyperglycemia and was markedly
reduced by 4-h insulin infusion in diabetic patients,but not in non-
diabetics (60). This clinical study demonstrated the pathological
role for high glucose in inducing, whereas for exogenous insulin
in reducing arginase activation. The exact molecular mechanisms
remained unclear. The proposed mechanisms by which diabetes
and hyperglycemia lead to up-regulation of arginase-1 resulting
in reduced NO-mediated dilation in human coronary arteries is
depicted in Figure 1.
In summary, recent findings, as highlighted in this brief review
underline the need for the investigations exploring the underly-
ing mechanisms responsible for up-regulated arginase in human
diabetes. Clinical studies emphasize the importance of those inves-
tigations that strive to elucidate the vascular effects of specific
arginase inhibitors, including their long-term efficacy and safety
in diabetic patients with CAD.
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